Last updated: February 25, 2026
What is the drug identified by NDC 69367-0296?
NDC 69367-0296 corresponds to Acalabrutinib (Calquence), a Bruton tyrosine kinase (BTK) inhibitor used primarily for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is marketed by AstraZeneca.
How does the current market landscape look?
Market size and sales data
- Global sales: Estimated at $600 million in 2022. Growth driven by expanding indications and geographic expansion.
- U.S. market share: Holds approximately 80% of sales, with a growing presence in Europe and Asia.
- Competitive landscape:
- Primary competitor: Ibrutinib (Imbruvica, Pfizer)
- Recent entrant: Zanubrutinib (Brukinsa, BeiGene)
- Other alternatives: Multiple off-label BTK inhibitors and combination therapies
Therapeutic indications and patient populations
- First-line MCL and CLL.
- Relapsed/refractory cases.
- Growing use in Waldenström's macroglobulinemia (WM).
Regulatory status
- FDA approval: 2019 for MCL.
- Additional approvals: CLL/SLL in 2020.
- Market expansion: Approval in Europe (EMA) in 2020; approvals in the Asian markets are pending or granted.
Patent landscape and exclusivity
- Patent protections extend into 2030s.
- Pending patent litigations around formulation and combination uses.
What are the drivers and challenges for this drug's market?
Drivers
- Increasing prevalence of B-cell malignancies.
- Line extension possibilities into other hematologic indications.
- Orphan drug designation for certain indications, providing market exclusivity.
- Broadening hospital and outpatient adoption.
Challenges
- Pricing pressure from payers, especially in markets outside the U.S.
- Competition from generic or biosimilar BTK inhibitors post patent expiry.
- Adverse event profiles impacting treatment adherence.
Price projection analysis (2023–2030)
Current pricing structure
- Per-patient annual cost: Approximately $125,000 in the U.S.
- Reimbursement: Secured via insurance, with negotiated discounts.
Projected pricing trends
| Year |
Estimated Price per Patient |
Major Factors |
| 2023 |
$125,000 |
Stable, no significant patent expiration expected. |
| 2025 |
$115,000 |
Implementation of value-based pricing models. |
| 2027 |
$105,000 |
Introduction of biosimilar competitors in pivotal markets. |
| 2030 |
$90,000 |
Likely patent expiry approaches; biosimilar market entry. |
Market penetration assumptions
- U.S.: 30% penetration in eligible patient populations by 2025.
- Europe and Asia: Growing to 20% of global market share by 2030, with slower initial uptake due to regulatory delays.
Price reduction factors
- Biosimilar entry: Expected to drop original drug prices by 30% post-2027.
- Payer negotiations: Projected discounts of 15-20% on list prices.
- Generics: Potential emergence post-2030, with further price erosion.
Revenue outlook
- 2022: $600 million.
- 2023–2025: Compound annual growth rate (CAGR) of 10–15%, driven by increased adoption.
- 2025–2030: Growth slows as market saturation occurs, with stabilization and price erosion.
Strategic implications
- AstraZeneca and partners should monitor biosimilar pathways and patent landscapes.
- Pricing strategies should account for regional regulatory differences.
- Expanding indication labels can sustain revenue growth beyond 2025.
Key Takeaways
- NDC 69367-0296 (Acalabrutinib) has established itself as a key treatment in B-cell malignancies, with a stable and growing market.
- Current pricing is approximately $125,000 per year in the U.S., with projections down to $90,000 by 2030 due to biosimilar competition.
- Market growth hinges on indication expansion, geographic penetration, and patent protection.
- Competitive pressure is increasing from biosimilars and other BTK inhibitors.
- Pricing strategies should be adaptable to regional differences and emerging competition.
FAQs
Q1: When will biosimilars for acalabrutinib likely hit the market?
Biosimilars are expected after patent expiry, anticipated around 2030–2032 in major markets.
Q2: How does the price of acalabrutinib compare internationally?
US prices are generally higher; European and Asian markets may see prices between 30-50% lower due to pricing regulations and negotiations.
Q3: Which indications are most commercially valuable?
First-line treatment for MCL and CLL generate the highest revenues. Expanding into WM and other B-cell disorders also offers growth prospects.
Q4: What are the risks to revenue projections?
Patent challenges, accelerated biosimilar entry, regulatory delays, or unexpected adverse events could suppress revenues.
Q5: How have recent regulatory decisions affected market outlook?
FDA and EMA approvals in multiple indications have boosted sales forecasts; delayed approvals in certain markets could hinder growth.
References
- IQVIA. (2022). Global Oncology Drug Sales Data.
- AstraZeneca. (2022). Calquence (Acalabrutinib) Product Information.
- EMA. (2022). Regulatory Status of Calquence.
- EvaluatePharma. (2022). World Market Intelligence for Oncology Drugs.
- U.S. Food and Drug Administration. (2020). Labeling and Indication Approvals for Acalabrutinib.
[1] IQVIA. (2022). Global Oncology Drug Sales Data.
[2] AstraZeneca. (2022). Calquence (Acalabrutinib) Product Information.
[3] EMA. (2022). Regulatory Status of Calquence.
[4] EvaluatePharma. (2022). World Market Intelligence for Oncology Drugs.
[5] U.S. Food and Drug Administration. (2020). Labeling and Indication Approvals for Acalabrutinib.
